Enter vial size, bacteriostatic water volume and your own amount to get concentration, syringe units and amounts per vial. NAD+ is a coenzyme, not a peptide, and has no approved dose — this page does the arithmetic, not the recommendation. The compound itself is covered in the NAD+ guide.
A 500 mg vial of NAD+ reconstituted with 5 mL of bacteriostatic water gives a concentration of 100 mg/mL, or 1 mg per unit on a U-100 syringe.
Defaults: 500 mg is the most common labelled vial among the NAD+ tests on file (197 of the 300 most recent, 11 Sep 2026). 5 mL was chosen for simple arithmetic (100 mg/mL = 1 mg per unit on a U-100 syringe) and is not a sourced protocol. There is no approved NAD+ dose, and Peptigrity does not recommend one, so the dose field starts empty.
Draw the syringe up to
Enter your own amount to see the draw. Add 5 mL of water to your 500 mg vial first.
NAD+ figures only mean something once you state the concentration. On a U-100 syringe one unit is 0.01 mL, so at 50 mg/mL one unit holds 0.5 mg and a 1 mg amount is 2.0 units; at 100 mg/mL the same amount is 1.0 unit. NAD+ is a coenzyme, not a peptide, and no approved label or Peptigrity page sets a dose for it. The arithmetic here is deterministic; the dose is not.
| Concentration | Per unit (U-100) | Units per 1 mg | Volume per 1 mg |
|---|---|---|---|
| 10 mg/mL | 100 mcg | 10.0 units | 0.10 mL |
| 20 mg/mL | 200 mcg | 5.0 units | 0.05 mL |
| 25 mg/mL | 250 mcg | 4.0 units | 0.04 mL |
| 50 mg/mL | 500 mcg | 2.0 units | 0.02 mL |
| 100 mg/mL | 1 mg | 1.0 units | 0.01 mL |
In words: NAD+ at 50 mg/mL delivers 500 mcg per unit, so a 50 mg amount is 100.0 units — a full 1 mL U-100 barrel. At 100 mg/mL the same 50 mg is 50.0 units. At the milligram scale NAD+ is handled on, small concentration errors move large absolute amounts.
NAD+ is nicotinamide adenine dinucleotide, formula C₂₁H₂₇N₇O₁₄P₂, molecular weight 663.4 g/mol — a dinucleotide coenzyme with no amino acids and no peptide bonds. It appears in research-chemical catalogues beside peptides only because longevity buyers shop for both. That changes what a certificate has to prove: identity confirmation needs mass spectrometry appropriate to dinucleotides. The reconstitution arithmetic, by contrast, is chemistry-agnostic — mg ÷ mL is mg/mL whatever the molecule. Category: immune and longevity peptides.
NAD+ has no approved dose and no dose ladder in our fact base. The compound page states no dose. The only dose figure with a trial attached is 2,000 mg per day of oral nicotinamide riboside for 12 weeks in 40 participants (Dollerup 2018) — a precursor, swallowed, with a null result on its primary outcomes. No injected NAD+ amount in our fact base has a trial or a regulator behind it, which is why the dose field above starts empty.
| Route or figure | What our fact base supports | Evidence level |
|---|---|---|
| Regulator-approved NAD+ dose | None exists (as of May 2026) | No approval anywhere |
| Peptigrity dose | None — Peptigrity does not recommend one | Declined |
| IV clinic protocols | “Vary widely.” No figure published | Convention; varies by clinic |
| Subcutaneous injection | Named as a route; no amount, frequency or duration attached | Route named; dose not published |
| Oral nicotinamide riboside, 2,000 mg/day, 12 weeks | Dollerup 2018, n=40 — a precursor, not injected NAD+ | Human RCT — precursor, null on primary outcomes |
The evidence on NAD+ and its precursors is set out in the NAD+ boosters deep-dive.
Draw volumes depend entirely on the concentration you mixed, and because NAD+ is handled in whole milligrams the numbers run out of syringe fast. The table is arithmetic across four concentrations so you can see where the barrel ceiling falls.
| Amount | At 25 mg/mL | At 50 mg/mL | At 100 mg/mL | At 200 mg/mL |
|---|---|---|---|---|
| 1 mg | 4.0 units (0.04 mL) | 2.0 units (0.02 mL) | 1.0 units (0.01 mL) | 0.5 units (0.005 mL) |
| 5 mg | 20.0 units (0.20 mL) | 10.0 units (0.10 mL) | 5.0 units (0.05 mL) | 2.5 units (0.025 mL) |
| 10 mg | 40.0 units (0.40 mL) | 20.0 units (0.20 mL) | 10.0 units (0.10 mL) | 5.0 units (0.05 mL) |
| 25 mg | 100.0 units (1.00 mL) | 50.0 units (0.50 mL) | 25.0 units (0.25 mL) | 12.5 units (0.13 mL) |
| 50 mg | 200.0 units — does not fit a 1 mL barrel | 100.0 units (1.00 mL) | 50.0 units (0.50 mL) | 25.0 units (0.25 mL) |
| 100 mg | 400.0 units — does not fit a 1 mL barrel | 200.0 units — does not fit a 1 mL barrel | 100.0 units (1.00 mL) | 50.0 units (0.50 mL) |
Two ceilings bite at opposite ends. Any cell over 100 units does not fit one barrel — reconstitute at a higher concentration. Any cell under about 2 units is below readable resolution — at half a unit, a one-unit misread is a 200% error, so reconstitute at a lower concentration. The same method for other compounds: how to calculate peptide doses.
NAD+ reconstitution is a choice, not a recipe — no label sets a diluent volume for it, so pick the volume that puts your intended amount in a readable part of the syringe. Step 1: divide your amount in mg by the units you want to draw, multiply by 100 for the target mg/mL, then divide the vial mg by that to get the water volume. Step 2: inject the bacteriostatic water slowly against the inside glass wall and swirl gently; do not shake. Step 3: refrigerate. Peptigrity publishes no in-use period for NAD+, so treat any “discard after N days” figure you have seen as borrowed from a compound that had a label. Procedure and diluent choice are covered once, elsewhere: how to reconstitute a NAD+ vial and the bacteriostatic water guide.
A vial lasts as many amounts as the label mass divided by the amount — the water volume changes nothing about it. A 500 mg vial at 10 mg per amount provides about 50; a 100 mg vial at 25 mg provides about 4. How long that is in weeks depends on a frequency our fact base does not publish.
| Vial | At 5 mg | At 10 mg | At 25 mg | At 50 mg |
|---|---|---|---|---|
| 100 mg | 20 | 10 | 4 | 2 |
| 250 mg | 50 | 25 | 10 | 5 |
| 500 mg | 100 | 50 | 20 | 10 |
| 1,000 mg | 200 | 100 | 40 | 20 |
NAD+ is one of the most-tested compounds on this platform. It holds a Purity Index of 99.13, ranking 57th of 64 indexed compounds with a purity tier of “Excellent” — the index band at the top is narrow, so the rank alone misleads. 356 tests in the recency-weighted Purity Index (as of 1 September 2026); 359 tests on file on the compound page, averaging 99.09% HPLC purity (as of September 2026). That establishes vendors are broadly selling the correct molecule. It says nothing about efficacy, dosing or endotoxin. Records: NAD+ lab test records and the Purity Index.
There is currently no answer to this in the price layer. As of September 2026 the NAD+ price tracker has no comparable offer to report: 0 shops are in stock, the one identified listing is a multi-vial kit and so falls outside the per-milligram comparison, and 134 of the 135 known NAD+ sellers are evidenced by a lab test rather than a live listing. Cost per amount cannot be calculated from this data, and this page will not estimate one.
These figures exclude shipping, taxes and customs charges; coupon codes and bulk discount tiers; multi-vial kits; and email-only or account-required pricing. They are the lowest tracked price, not the lowest payable price. The multi-vial-kit exclusion is precisely why NAD+ shows no price at all.
| Question | Status | As of |
|---|---|---|
| Approved for longevity, aging or related indications | No — not approved anywhere in the world | May 2026 |
| Legal to purchase as a research chemical | Yes, for laboratory use in most jurisdictions | September 2026 |
| Oral precursors NR / NMN | Sold as dietary supplements in most markets; NMN exclusion reversed 29 September 2025 | September 2026 |
| WADA Prohibited List | NAD+ and its precursors are not on it | 2026 list |
| Injectable-product safety | FDA classified a Class I recall of NAD+ injection produced by GenoGenix, for endotoxin contamination | 21 October 2025 |
A Class I recall is the FDA's most serious classification, and endotoxin is a contaminant an HPLC purity certificate does not test for — see endotoxin testing and LAL assay interpretation. Direct NAD+ administration commonly produces transient side effects including flushing, headache, gastrointestinal upset and mild blood pressure changes, particularly during infusion at higher doses.
NAD+ is the active coenzyme; NMN and NR are precursors the body converts into it. Only NAD+ is reconstituted and drawn — the precursors are swallowed, and the human trial evidence in our fact base is about them: NR raises blood NAD+ up to 2.7-fold (Trammell 2016) and about 60% (Martens 2018) without, so far, a measurable gain in mitochondrial function, insulin sensitivity or physical performance. IV NAD+ “performed worse than IV nicotinamide riboside, with more adverse events and infusion times two to four times longer.” None of the three is a peptide. More: peptides for energy and mitochondrial function.
No. NAD+ is a small dinucleotide molecule, not a peptide — formula C₂₁H₂₇N₇O₁₄P₂, molecular weight 663.4 g/mol, with no amino acids and no peptide bonds. It is grouped with peptides in research-chemical catalogues because of overlapping research interest in longevity and metabolic health, not because of any chemical similarity.
It depends entirely on the concentration. At 50 mg/mL, 10 mg is 20.0 units on a U-100 syringe; at 100 mg/mL it is 10.0 units; at 25 mg/mL it is 40.0 units. Units = (amount in mg ÷ concentration in mg/mL) × 100. A units figure quoted without a concentration cannot be used.
None. There is no approved NAD+ dose, and Peptigrity does not recommend one — IV clinic protocols for NAD+ vary widely. NAD+ is not approved for any longevity, anti-aging or aging-related indication anywhere in the world as of May 2026, and this calculator performs arithmetic on the amount you enter.
There is no standard volume and no label to specify one. Work backwards: pick the number of units you want to draw for your amount, convert that to a target concentration, then divide the vial mg by it. Aim for a draw between roughly 10 and 100 units, where a one-unit misread stays a small proportional error.
NAD+ is the active coenzyme; NMN and NR are precursors the body converts to NAD+. Oral NMN and NR are widely sold as dietary supplements; direct NAD+ administration is typically by IV or subcutaneous injection because oral NAD+ has poor bioavailability. The FDA exclusion of NMN from the supplement definition was reversed on 29 September 2025.
No. The indexed tests establish identity and purity, averaging 99.09%. They do not test for endotoxin. On 21 October 2025 the FDA classified a Class I recall of a GenoGenix NAD+ injection for endotoxin contamination. Identity confirmation for NAD+ also requires mass spectrometry appropriate to dinucleotides.